الفهرس 
LncRNA MALAT-1 and MiRNA-9 in Egyptian patients with psoriasis
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Background and aim: Psoriasis is a chronic debilitating disease affecting1-2% of the white population. It is characterized by recurrent episodes of red, scaly, raised skin plaques that develop within seemingly normal skin and is triggered by a large number of factors, such as drugs, stress, physical injury to the skin and infection. Our aim was to detect the expression of serum and tissue (lesion and non-lesion) of LncRNA MALAT-1 and MiRNNA-9 used as biomarkers for psoriasis. Subject and Methods: Blood samples were taken from 20 psoraiatic patients as well as 20 controls. 4 mm punch biopsy was taken from each lesional and non lesional skin of psoriasis patient and controls. The following were done: An informed consent, history taking, and clinical assessment of the disease: extent of disease (%), disease severity: using PASI score and assessment of the severity of the biopsied plaque (BPSS). Serum was separated for detection of: LncRNA MALAT-1 and miRNNA-9 expressions by real time RT-PCR. Results: The results revealed significant increase in the expression of MALAT-1 in lesional and non-lesional skin and serum of psoriatic patients than controls. Also there was statistical significant increase in serum MiRNA-9 in patients than controls. Meanwhile, its tissue level was significantly decreased in patients than controls